Market Intelligence, Clinical Progress, and High-Purity Reagents for Lymphoma Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD30 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD30 (TNFRSF8) ECD-Fc Fusion Protein. High purity (>95%), Endotoxin <1 EU/µg. HEK293 Expressed (Native Glycosylation). Sequence Verified. Theoretical MW confirmed. | View CD30 Products |
| Gene Delivery | CD30 (TNFRSF8) Premade Lentivirus. Full-length ORF for stable cell line construction. High titer (>10^8 TU/ml). Ideal for internalization and cell-based cytotoxicity assays. | View CD30 Products |
| Benchmark Ab | Anti-CD30 (Brentuximab Vedotin Sequence). Recombinant positive control. Sequence Verified. Theoretical MW confirmed. | View CD30 Products |
| Validator | CD30 siRNA Set (3 unique targets). For knockdown verification and specificity confirmation. | View CD30 Products |
| Related Target A | TNFSF8 (CD30L) Recombinant Protein. Counter-receptor for binding assays, ligand competition, and co-crystal studies. | View TNFSF8 Products |
| Related Target B | PDCD1 (PD-1) Recombinant Protein. Synergistic checkpoint combination in lymphoma immunotherapy. | View PDCD1 Products |
| Related Target C | TNFRSF7 (CD27) Recombinant Protein. TNFR superfamily member; critical for off-target selectivity screening. | View TNFRSF7 Products |
| Related Target D | CD19 Recombinant Protein. Comparative B-cell marker for dual-targeting lymphoma strategies. | View CD19 Products |
| Related Target E | CD25 (IL-2RA) Recombinant Protein. Co-expressed marker in activated T-cell lymphomas; target for bispecifics. | View CD25 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| ADC Internalization Efficiency | High-purity ECD-Fc (>95%) with native conformational epitopes preserved for accurate conjugation chemistry optimization and internalization kinetics. |
| Cross-species Toxicology (Cyno/Mouse) | Human/Mouse/Cyno ortholog proteins available with >95% purity, sequence verified by mass spec. |
| TNFR Superfamily Counter-screening | Homolog panel (TNFRSF1A, 1B, 4, 7, 9) strictly verified by mass spec for selectivity assays. |
| Lack of Validated Controls | Clinical Benchmark Antibodies (Brentuximab biosimilar) and validated siRNA included for specificity checks. |
| False Positives in Binding Assays | Endotoxin-controlled (<1 EU/µg) proteins eliminate LPS-mediated artifacts. |
| Soluble CD30 Sink Effect & Binding Affinity | High-purity ECD-Fc (theoretical MW verified) for precise SPR/BLI kinetic measurements and competition assays. |
| CAR-T Cytotoxicity Assay Artifacts | Validated Lentivirus for generating native-conformation stable cell lines, minimizing abnormal target expression. |
Live CD30 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD30-targeted therapeutics has been validated by the commercial success of brentuximab vedotin in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). The landscape is now intensifying, with major players shifting focus from traditional MMAE-based ADCs to next-generation modalities: novel-payload ADCs (e.g., PBD dimers, topoisomerase inhibitors), bispecific antibodies (CD30×CD16A, CD30×CD3), and CAR-T cell therapies. Key challenges include overcoming dose-limiting toxicities (peripheral neuropathy), resistance via CD30 downregulation or MDR1 overexpression, and the "soluble CD30 sink" effect that can neutralize antibodies in circulation. The next wave of R&D targets improved therapeutic indices, combination regimens with checkpoint inhibitors (e.g., PD-1/PD-L1), and expansion into indications such as cutaneous T-cell lymphoma and autoimmune diseases. Biosimilar competition is also expected as brentuximab vedotin approaches patent expiry.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Seagen/Pfizer, Takeda, Bristol Myers Squibb | Hodgkin Lymphoma, ALCL, PTCL | Internalization Assay (need high-purity ECD-Fc with native glycosylation; Lentivirus stable cell lines) |
| CAR-T | Tessa Therapeutics, Novartis, Academic/ Biotech pipelines | Relapsed/Refractory HL, ALCL | Cytotoxicity & fratricide evaluation (need Lentivirus for target cell engineering; siRNA for specificity) |
| Bispecific | Affimed (CD30×CD16A), Emerging Biotechs (CD30×CD3) | Peripheral T-cell Lymphoma, relapsed/refractory lymphoma | Heterodimer binding & NK cell engager assays (need ortholog proteins and ligand competition) |
| Monoclonal/Enhanced | Various fast-followers | Cutaneous T-cell Lymphoma | ADCC/ADCP assays (need HEK293-expressed proteins with native glycosylation) |
| Small Molecule | Preclinical | Autoimmune (CD30+ T-cells) | Selectivity assay (need mutant vs. WT proteins and family counter-screening) |
Key Genetic Variants & Mutations
Several single nucleotide variants in TNFRSF8 have been reported in dbSNP and UniProt (P28908). Notable examples include rs2230624 (VAR_054213, VAR_018753) and rs1763642 (VAR_055257). These polymorphisms may affect the extracellular domain or protein stability, potentially influencing antibody binding or disease susceptibility. High-purity wild-type and mutant proteins are essential for evaluating the impact of such variants on drug candidate affinity and selectivity.